Nanoscope Secures Japan MHLW Sakigake and Orphan Drug Designations Across Inherited Retinal Diseases - A First for a Retinal Gene Therapy

Nanoscope Secures Japan MHLW Sakigake and Orphan Drug Designations Across Inherited Retinal Diseases - A First for a Retinal Gene Therapy

Japan's Ministry of Health, Labour and Welfare (MHLW) grants MCO-010 Sakigake (Pioneering Regenerative Medical Product) and Orphan Drug designations, enabling an accelerated regulatory pathway for patients with severe inherited retinal diseases...

MCO (MyComplianceOffice) Partners with FirmScribe to Deliver iMessage Retention Capabilities

MCO (MyComplianceOffice) Partners with FirmScribe to Deliver iMessage Retention Capabilities

NEW YORK, Dec. 4, 2025 /PRNewswire/ -- MCO (MyComplianceOffice), a leading provider of integrated compliance technology solutions, has established a strategic partnership with FirmScribe, the industry-recognized leader in iMessage archiving for...

NYSE Content Advisory: Pre-Market Update + S&P 500 Hits 6,900 for First Time

NYSE Content Advisory: Pre-Market Update + S&P 500 Hits 6,900 for First Time

NEW YORK, Oct. 29, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content...

MCO (MyComplianceOffice) Rises to #42 in the Chartis RiskTech100 2026

MCO (MyComplianceOffice) Rises to #42 in the Chartis RiskTech100 2026

NEW YORK, Oct. 23, 2025 /PRNewswire/ -- MCO (MyComplianceOffice) has advanced to #42 in the 2026 Chartis RiskTech100, marking its third straight year of upward movement and another appearance among the world's top 50 risk-technology providers. The...

menu
menu